Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:57:03.512Z.
Consensus retrieved: 2026-10-06T11:54:53.904Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:57:03.512Z.
Quote observation: 2026-10-06T14:55:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea8f5c362e28cab1379660d94c14b865908cd29a247cab29e6d5b71901c6c862
Forward PE Ratio (N/A) = Dated Quote Price ($1.21) / Consensus Forward EPS ($-0.04)
FORWARD PE RATIO
N/A
Geron Corporation
Market Cap
$776.24M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Geron Corporation (GERN) | $776.24M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $768.31M | N/A |
| AdaptHealth Corp. (AHCO)vs › | $784.35M | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $785.44M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $750.73M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $750.01M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $748.60M | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 10.81 |
| Apnimed, Inc. (APMD)vs › | $807.90M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.21, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.04 | $-0.05 – $-0.03 | 3 | n/m |
| 2027-12-31 | $0.07 | $0.02 – $0.16 | 3 | 16.4x |
| 2028-12-31 | $0.25 | $0.11 – $0.58 | 4 | 4.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
